Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
54.80
-0.57 (-1.03%)
At close: Jan 17, 2025, 4:00 PM
54.60
-0.20 (-0.36%)
After-hours: Jan 17, 2025, 6:40 PM EST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 373 employees as of December 31, 2023. The number of employees decreased by 20 or -5.09% compared to the previous year.
Employees
373
Change (1Y)
-20
Growth (1Y)
-5.09%
Revenue / Employee
$2,539,826
Profits / Employee
$1,052,190
Market Cap
6.97B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | 132 | -149 | -53.02% |
Dec 31, 2018 | 281 | 26 | 10.20% |
Dec 31, 2017 | 255 | -4 | -1.54% |
Dec 31, 2016 | 259 | 43 | 19.91% |
Dec 31, 2015 | 216 | 63 | 41.18% |
Dec 31, 2014 | 153 | -17 | -10.00% |
Dec 31, 2013 | 170 | 18 | 11.84% |
Dec 31, 2012 | 152 | 17 | 12.59% |
Dec 31, 2011 | 135 | 33 | 32.35% |
Dec 31, 2010 | 102 | -38 | -27.14% |
Dec 31, 2009 | 140 | 10 | 7.69% |
Dec 31, 2008 | 130 | 38 | 41.30% |
Dec 31, 2007 | 92 | 52 | 130.00% |
Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
HALO News
- 12 days ago - Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PRNewsWire
- 14 days ago - Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - PRNewsWire
- 17 days ago - Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha
- 21 days ago - Halozyme: Recent Approvals Alter My Appetite - Seeking Alpha
- 21 days ago - Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - PRNewsWire
- 21 days ago - Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy - PRNewsWire
- 21 days ago - Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications - PRNewsWire
- 7 weeks ago - Halozyme to Present at Upcoming Investor Conferences - PRNewsWire